Outcome of cardioverter-defibrillator implant in patients with arrhythmogenic right ventricular cardiomyopathy

The aim of the present study was to investigate outcomes of implantable cardioverter-defibrillator (ICD) treatment in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). We reviewed baseline/follow-up data of 15 consecutive ARVC patients (mean age 55 +/- 15 years) and 30 randomly d...

Full description

Saved in:
Bibliographic Details
Published in:Heart and vessels 2007-05, Vol.22 (3), p.184-192
Main Authors: Boriani, Giuseppe, Artale, Paolo, Biffi, Mauro, Martignani, Cristian, Frabetti, Lorenzo, Valzania, Cinzia, Diemberger, Igor, Ziacchi, Matteo, Bertini, Matteo, Rapezzi, Claudio, Parlapiano, Mario, Branzi, Angelo
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Anti-Arrhythmia Agents - therapeutic use
Arrhythmogenic Right Ventricular Dysplasia - therapy
Cardiac arrhythmia
Cardiovascular disease
Clinical outcomes
Combined Modality Therapy
Defibrillators, Implantable - adverse effects
Female
Humans
Male
Middle Aged
Survival Rate
Transplants & implants
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of the present study was to investigate outcomes of implantable cardioverter-defibrillator (ICD) treatment in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). We reviewed baseline/follow-up data of 15 consecutive ARVC patients (mean age 55 +/- 15 years) and 30 randomly drawn patients with coronary artery disease (CAD) (mean age 60 +/- 10 years) with matching durations of follow-up (all implanted with ICDs for primary/secondary prevention of sudden death). At implant, appropriate placement of the RV lead was more difficult in ARVC patients. During follow-up (median 41 months), appropriate interventions for any ventricular tachyarrhythmias occurred in 8 (53%) ARVC patients and 17 (57%) CAD patients, but the occurrence of high rate (>240 beats/min) ventricular tachyarrhythmias was higher in ARVC patients. Inappropriate ICD interventions occurred in 5 (33%) ARVC patients and 10 (33%) CAD patients. Lead-related adverse events requiring surgical revision occurred in 7 (47%) ARVC patients as compared with 4 (13%) CAD patients (P = 0.0004). While ICD implantation is highly effective for prevention of sudden death in ARVC, it does carry elevated burdens of long-term lead-related adverse events. These findings underline the need of careful follow-up in ARVC aimed at early recognition of complications that can impair ICD function.
ISSN:0910-8327
1615-2573
DOI:10.1007/s00380-006-0963-8